Aytu BioPharma (AYTU) Q4 2026 Financial Results Summary
QuoteReporter
Aytu BioPharma (AYTU) Q4 2026: Revenue Growth Amidst Challenges — Cautiously Optimistic
Aytu BioPharma reported its fourth quarter fiscal 2026 results, revealing a net revenue increase of $1.0 million or +6.4% year-over-year, rising to $16.1 million from $15.1 million in the prior-year quarter. This growth is a positive sign for shareholders, indicating a potential turnaround despite ongoing challenges in the ADHD and Pediatric portfolios.
Key Financial Metrics:
- Q4 Fiscal 2026 Net Revenue: $16.1 million, up from $15.1 million in Q4 fiscal 2025 (+6.4% YoY).
- EXXUA Net Revenue: $3.9 million in Q4 fiscal 2026, marking its first full quarter post-launch.
- ADHD Portfolio Net Revenue: $10.4 million, down from $13.1 million in Q4 fiscal 2025.
- Pediatric Portfolio Net Revenue: $1.8 million, down from $2.0 million in Q4 fiscal 2025.
- Net Loss: Approximately break-even at less than ($0.1) million, significantly improved from a net loss of ($19.8) million in Q4 fiscal 2025.
- Adjusted EBITDA: $0.5 million, compared to $2.0 million in Q4 fiscal 2025.
Analyst Opinion:
This quarter can be viewed as a cautiously optimistic outcome for shareholders. The increase in net revenue, particularly from the newly launched EXXUA, suggests that the company is making strides in its commercialization efforts. The significant reduction in net loss from ($19.8) million to approximately break-even is a noteworthy improvement, indicating better operational efficiency and cost management. However, the decline in revenue from the ADHD and Pediatric portfolios raises concerns about the sustainability of growth moving forward.
Additional Insights:
- EXXUA Performance: The launch of EXXUA has shown promising results, with total prescriptions reaching 3,323 in Q4, up approximately 138% from 1,398 in Q3 fiscal 2026. This momentum is crucial as the company aims to establish EXXUA as a key treatment option for major depressive disorder.
- ADHD and Pediatric Portfolio Challenges: The decline in revenue from the ADHD portfolio, which fell to $10.4 million from $13.1 million, is attributed to the prioritization of EXXUA and increased generic competition. The Pediatric portfolio also saw a decrease, reflecting reduced promotional efforts.
- Cash Position: Aytu reported a cash balance of $26.3 million as of June 30, 2026, providing a stable liquidity position to support ongoing investments in EXXUA.
Forward-Looking Catalysts:
Investors should closely monitor the continued performance of EXXUA in the upcoming quarters, particularly as the company ramps up its commercialization efforts. Key indicators to watch include prescription trends, market penetration, and the impact of promotional activities on both the ADHD and Pediatric portfolios. Additionally, any updates on operational efficiencies and cost management will be critical as Aytu aims to achieve consistent positive adjusted EBITDA levels in fiscal 2027.
In summary, while Aytu BioPharma faces challenges, the positive revenue growth and improved financial metrics in Q4 fiscal 2026 provide a foundation for cautious optimism among shareholders.
Unaudited Consolidated Statements of Operations
(in thousands, except share and per share data)
Note: All amounts in the table are in thousands.
| Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Twelve Months Ended June 30, 2026 | Twelve Months Ended June 30, 2025 |
|---|---|---|---|
| Net revenue: $16,100 | $15,100 | $57,500 | $66,000 |
| Cost of goods sold: $5,600 | $4,881 | $20,700 | $20,000 |
| Gross profit: $10,500 | $10,219 | $36,800 | $45,000 |
| Operating expenses | |||
| Selling and marketing expenses: $6,100 | $4,781 | $23,300 | $20,000 |
| General and administrative expenses: $4,300 | $3,696 | $19,200 | $17,000 |
| Restructuring and development expenses: $0 | $216 | $0 | $1,300 |
| Amortization of intangible assets: $761 | $921 | $2,492 | $3,600 |
| Restructuring costs: $0 | $0 | $0 | $2,100 |
| Impairment expense: $0 | $8,263 | $0 | $8,200 |
| Total operating expenses: $11,000 | $17,800 | $45,100 | $53,000 |
| Loss from operations: ($777) | ($7,600) | ($8,300) | ($7,000) |
| Other income (expense): $173 | ($1,200) | $713 | ($512) |
| Interest expense: ($383) | ($730) | ($1,800) | ($3,000) |
| Derivative warrant liabilities gain: $983 | ($9,800) | ($4,700) | ($1,000) |
| Loss from continuing operations: ($4) | ($19,000) | ($14,000) | ($13,000) |
| Income tax expense: ($11) | ($437) | ($21) | ($437) |
| Net loss from continuing operations: ($15) | ($19,000) | ($14,000) | ($14,000) |
| Net income (loss) from discontinued operations: $0 | $62 | $0 | $620 |
| Net loss before income tax: ($15) | ($19,000) | ($14,000) | ($13,000) |
| Net loss per share: ($0.01) | ($2.93) | ($1.16) | ($2.00) |
| Basic and diluted net income (loss) per share: $0 | $0.01 | $0 | $0.10 |
| Basic and diluted net loss: ($0.01) | ($2.92) | ($1.16) | ($2.00) |
Unaudited Consolidated Balance Sheets
(in thousands, except share data)
| ASSETS | June 30, 2026 | June 30, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $26,308 | $30,952 |
| Accounts receivable, net | $22,779 | $31,155 |
| Inventories | $6,860 | $11,434 |
| Prepaid expenses and other current assets | $5,814 | $5,638 |
| Total current assets | $61,761 | $79,179 |
| Non-current assets: | ||
| Property and equipment, net | $385 | $532 |
| Operating lease right-of-use assets | $857 | $1,061 |
| Intangible assets, net | $41,403 | $42,201 |
| Other non-current assets | $601 | $1,204 |
| Total non-current assets | $43,246 | $44,998 |
| Total assets | $105,007 | $124,177 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $11,284 | $10,601 |
| Accrued liabilities | $35,205 | $38,164 |
| Revolving credit facility | $6,074 | $9,063 |
| Current portion of debt | $1,857 | $1,857 |
| Other current liabilities | $239 | $3,379 |
| Total current liabilities | $54,659 | $63,064 |
| Non-current liabilities: | ||
| Debt, net of current portion | $9,101 | $10,895 |
| Derivative warrant liabilities | $1,199 | $26,334 |
| Other non-current liabilities | $4,774 | $4,918 |
| Total non-current liabilities | $15,074 | $42,147 |
| Stockholders’ equity: | ||
| Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding | $0 | $0 |
| Common stock, par value $.0001; 200,000,000 shares authorized; 10,728,208 and 8,976,913 shares issued and outstanding, respectively | $1 | $1 |
| Additional paid-in capital | $383,060 | $352,500 |
| Accumulated deficit | ($347,787) | ($333,535) |
| Total stockholders’ equity | $35,274 | $18,966 |
| Total liabilities and stockholders’ equity | $105,007 | $124,177 |
Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.
